论文部分内容阅读
目的:观察健心平律丸联合胺碘酮治疗阵发性心房颤动的疗效以及对患者基质金属蛋白酶2(MMP-2)的影响。方法:将65例气虚痰瘀证阵发性心房颤动患者随机分为治疗组32例、对照组33例。治疗组以健心平律丸联合小剂量胺碘酮治疗,对照组单纯服用胺碘酮治疗。2组患者均用药治疗3月。观察患者症状体征、心电图检查结果的变化,并在治疗前后对比MMP-2水平。结果:治疗组疗效优于对照组(P<0.05)。治疗前,2组MMP-2水平比较,差异无统计学意义(P>0.05)。用药3月后,2组MMP-2水平均较治疗前下降,差异均有统计学意义(P<0.05);治疗组MMP-2水平低于对照组,差异有统计学意义(P<0.05)。结论:健心平律丸联合胺碘酮治疗能降低阵发性房颤患者的MMP-2水平,效果优于单纯用胺碘酮治疗。
Objective: To observe the therapeutic effect of Jianxin Pingliwan combined with amiodarone on patients with paroxysmal atrial fibrillation and its effect on matrix metalloproteinase 2 (MMP-2). Methods: Sixty-five patients with paroxysmal atrial fibrillation with phlegm and phlegm syndrome were randomly divided into treatment group (32 cases) and control group (33 cases). The treatment group was treated with Jianxinpingluewan combined with low-dose amiodarone and the control group with amiodarone alone. 2 patients were treated with medication in March. Observe the symptoms and signs of patients, ECG changes in the results, and compared before and after treatment MMP-2 levels. Results: The curative effect in the treatment group was better than that in the control group (P <0.05). Before treatment, there was no significant difference in MMP-2 levels between the two groups (P> 0.05). After 3 months, the MMP-2 levels in both groups were significantly lower than those before treatment (P <0.05), and the levels of MMP-2 in the treatment group were lower than those in the control group (P <0.05) . Conclusion: Jianxin Pingru pills combined with amiodarone can reduce MMP-2 levels in patients with paroxysmal atrial fibrillation, the effect is better than the simple treatment with amiodarone.